SAB Biotherapeutics, Inc. 8-K

What Happened
SAB Biotherapeutics, Inc. (SABS) announced on January 12, 2026 that it posted an updated corporate presentation on its official website and filed a Form 8‑K under Item 7.01 (Regulation FD Disclosure) to disclose that posting. The presentation is included as Exhibit 99.1 to the filing. The company stated it has no obligation to update the presentation but may do so through its Investor Relations page or other public filings. The report was signed on behalf of the registrant by Samuel J. Reich on January 12, 2026.

Key Details

• Filing date: January 12, 2026 (Form 8‑K).
• Item disclosed: 7.01 — Regulation FD Disclosure.
• Exhibit: 99.1 — Corporate Presentation dated January 12, 2026 (posted on the company website).
• Company note: No duty to update the presentation, though updates may be posted or filed publicly.

Why It Matters
This filing notifies investors that SAB Biotherapeutics has refreshed its public corporate presentation, which may contain updated strategy, program status, or corporate highlights. The Form 8‑K itself does not provide new financial results or executive changes; it documents the disclosure under Regulation FD so all investors can access the same presentation materials. Investors who follow SABS should review the presentation on the company’s Investor Relations page and monitor future SEC filings or press releases for any substantive updates.